{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T12:07:48Z","timestamp":1769602068057,"version":"3.49.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T00:00:00Z","timestamp":1654560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T00:00:00Z","timestamp":1654560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Epidermal growth factor receptor (EGFR) activation is associated with increased production of interleukin 6 (IL6), which is intensified by radiotherapy (RT) induced inflammatory response. Elevated IL6 levels intensifies RT-induced anemia by upregulating hepcidin causing functional iron deficiency. Cetuximab, an EGFR inhibitor, has been associated with lower rates of anemia for locally advanced head and neck squamous cell carcinoma (HNSCC). We hypothesized that concomitant cetuximab could prevent RT-induced anemia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We queried our institutional head and neck cancers database for non-metastatic HNSCC cases that received RT with concomitant cetuximab or RT-only between 2006 and 2018. Cetuximab was administered for some high-risk cases medically unfit for platinum agents per multidisciplinary team evaluation. We only included patients who had at least one complete blood count in the 4\u2009months preceding and after RT. We compared the prevalence of anemia (defined as hemoglobin (Hb) below 12\u2009g\/dL in females and 13\u2009g\/dL in males) and mean Hb levels at baseline and after RT. Improvement of anemia\/Hb (resolution of baseline anemia and\/or an increase of baseline Hb \u22651\u2009g\/dL after RT), and overall survival (OS) in relation to anemia\/Hb dynamics were also compared.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 171 patients were identified equally distributed between cetuximab-plus-RT and RT-only groups. The cetuximab-plus-RT group had more locally-advanced stage, oropharyngeal and high grade tumors (<jats:italic>p\u2009&lt;\u20090.001<\/jats:italic> for all). Baseline anemia\/Hb were similar, however anemia after RT conclusion was higher in the cetuximab-plus-RT vs RT-only (63.5% vs. 44.2%; <jats:italic>p\u2009=\u20090.017<\/jats:italic>), with a mean Hb of 11.98\u2009g\/dL vs. 12.9\u2009g\/dL; <jats:italic>p\u2009=\u20090.003,<\/jats:italic> for both respectively. This contributed to significantly worse anemia\/Hb improvement for cetuximab-plus-RT (18.8% vs. 37.2%; <jats:italic>p\u2009=\u20090.007<\/jats:italic>). This effect was maintained after adjusting for other factors in multivariate analysis. The prevalence of iron, vitamin-B12 and folate deficiencies; and chronic kidney disease, was non-different. Baseline anemia was associated with worse OS (<jats:italic>p\u2009=\u20090.0052<\/jats:italic>) for the whole study cohort. Nevertheless, improvement of anemia\/Hb was only marginally associated with better OS (<jats:italic>p\u2009=<\/jats:italic>\u00a00.068).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In contrast to previous studies, cetuximab was not associated with lower rates of anemia after RT for nonmetastatic HNSCC patients compared to RT-alone. Dedicated prospective studies are needed to elucidate the effect of cetuximab on RT-induced anemia.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-022-09708-9","type":"journal-article","created":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T12:14:02Z","timestamp":1654604042000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Cetuximab and anemia prevention in head and neck cancer patients undergoing radiotherapy"],"prefix":"10.1186","volume":"22","author":[{"given":"Lucas","family":"Maahs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed I.","family":"Ghanem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radhika","family":"Gutta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swarn","family":"Arya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zaid","family":"Al Saheli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haythem","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Tam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farzan","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jawad","family":"Sheqwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,7]]},"reference":[{"issue":"5","key":"9708_CR1","doi-asserted-by":"publisher","first-page":"628","DOI":"10.6004\/jnccn.2012.0064","volume":"10","author":"GM Rodgers","year":"2012","unstructured":"Rodgers GM, Becker PS, Blinder M, Cella D, Chanan-Khan A, Cleeland C, et al. Cancer- and chemotherapy-induced Anemia. J Natl Compr Cancer Netw. 2012;10(5):628\u201353.","journal-title":"J Natl Compr Cancer Netw"},{"issue":"suppl 2","key":"9708_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1634\/theoncologist.5-suppl_2-1","volume":"5","author":"LB Harrison","year":"2000","unstructured":"Harrison LB, Shasha D, White C, Ramdeen B. Radiotherapy-associated Anemia: the scope of the problem. Oncologist. 2000;5(suppl 2):1\u20137.","journal-title":"Oncologist"},{"issue":"2","key":"9708_CR3","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/S0093-7754(01)90214-3","volume":"28","author":"L Harrison","year":"2001","unstructured":"Harrison L, Shasha D, Shiaova L, White C, Ramdeen B, Portenoy R. Prevalence of Anemia in Cancer Pateints undergoing radiation therapy. Semin Oncol. 2001;28(2):54\u20139.","journal-title":"Semin Oncol"},{"issue":"Suppl 2","key":"9708_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1159\/000067147","volume":"63","author":"L Harrison","year":"2002","unstructured":"Harrison L, Shasha D, Homel P. Prevalence of anemia in cancer patients undergoing radiotherapy: prognostic significance and treatment. Oncology. 2002;63(Suppl 2):11\u20138.","journal-title":"Oncology."},{"key":"9708_CR5","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1002\/(ISSN)1097-0142","volume":"91","author":"JJ Caro","year":"2001","unstructured":"Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer. 2001;91:2214\u201321. https:\/\/doi.org\/10.1002\/(ISSN)1097-0142.","journal-title":"Cancer."},{"issue":"Suppl 2","key":"9708_CR6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1634\/theoncologist.5-suppl_2-13","volume":"5","author":"P Kumar","year":"2000","unstructured":"Kumar P. Impact of Anemia in patients with head and neck Cancer. Oncologist. 2000;5(Suppl 2):13\u20138. https:\/\/doi.org\/10.1634\/theoncologist.5-suppl_2-13.","journal-title":"Oncologist."},{"key":"9708_CR7","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S0360-3016(98)00062-5","volume":"41","author":"P Warde","year":"1998","unstructured":"Warde P, O\u2019Sullivan B, Bristow RG, et al. T1\/T2 glottic cancer managed by external beam radiotherapy: the influence of pretreatment hemoglobin on local control. Int J Radiat Oncol Biol Phys. 1998;41:347\u201353.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"9708_CR8","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1016\/j.jcms.2016.07.003","volume":"44","author":"D Rades","year":"2016","unstructured":"Rades D, Seidl D, Janssen S, Wollenberg B, Hakim SG, Schild SE. The effect of low hemoglobin levels on outcomes of radiotherapy following microscopically complete resection of locally advanced SCCHN: implications for the future. J Craniomaxillofac Surg. 2016;44(9):1441\u20134. https:\/\/doi.org\/10.1016\/j.jcms.2016.07.003 Hoff CM. Importance of hemoglobin concentration and its modification for the outcome of head and neck cancer patients treated with radiotherapy. Acta Oncol 2012;51:419\u201332.","journal-title":"J Craniomaxillofac Surg"},{"issue":"2","key":"9708_CR9","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/ajh.23628","volume":"89","author":"JA Gilreath","year":"2014","unstructured":"Gilreath JA, Stenehjem DD, Rodgers GM. Diagnosis and treatment of cancer-related anemia. Am J Hematol. 2014;89(2):203\u201312.","journal-title":"Am J Hematol"},{"issue":"1","key":"9708_CR10","first-page":"12","volume":"127","author":"J Overgaard","year":"2018","unstructured":"Overgaard J, Hoff CM, Hansen HS, et al. DAHANCA 10 \u2013 effect of darbepoetin alfa and radiotherapy in the treatment of squamous cell carcinoma of the head and neck. A multicenter, open-label, randomized, phase 3 trial by the Danish head and neck cancer group. Int J Radiat Oncol Biol Phys. 2018;127(1):12\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"9708_CR11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1748-717X-1-1","volume":"1","author":"M Zimmermann","year":"2006","unstructured":"Zimmermann M, Zouhair A, Azria D, et al. The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications. Radiat Oncol. 2006;1:11. https:\/\/doi.org\/10.1186\/1748-717X-1-1.","journal-title":"Radiat Oncol"},{"key":"9708_CR12","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.cytogfr.2018.04.002","volume":"41","author":"K Ray","year":"2018","unstructured":"Ray K, Ujvari B, Ramana V, Donald J. Cross-talk between EGFR and IL-6 drives oncogenic signaling and offers therapeutic opportunities in cancer. Cytokine Growth Factor Rev. 2018;41:18\u201327.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"9","key":"9708_CR13","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.bulcan.2015.06.001","volume":"102","author":"N Grellier","year":"2015","unstructured":"Grellier N, Deray G, Yousfi A, Khodari W, Bouaita R. Belkacemi Y. Carence martiale fonctionnelle, inflammation et fatigue apr\u00e8s radioth\u00e9rapie Functional iron deficiency, inflammation and fatigue after radiotherapy. Bull Cancer. 2015;102(9):780\u20135. https:\/\/doi.org\/10.1016\/j.bulcan.2015.06.001 Epub 2015 Jul 31. PMID: 26235415. French.","journal-title":"Bull Cancer"},{"issue":"6","key":"9708_CR14","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMoa053422","volume":"354","author":"JA Bonner","year":"2006","unstructured":"Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567\u201378. https:\/\/doi.org\/10.1056\/NEJMoa053422 PMID: 16467544.","journal-title":"N Engl J Med"},{"key":"9708_CR15","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1200\/JCO.2013.53.9163","volume":"32","author":"PM Harari","year":"2014","unstructured":"Harari PM, Harris J, Kies MS, Myers JN, Jordan RC, Gillison ML, et al. Postoperative Chemoradiotherapy and Cetuximab for high-risk squamous cell carcinoma of the head and neck: radiation therapy oncology group RTOG-0234. J Clin Oncol. 2014;32:2486\u201395.","journal-title":"J Clin Oncol"},{"key":"9708_CR16","unstructured":"NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers, Version 3; 2021. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/head-and-neck.pdf. Accessed June 21, 2021."},{"issue":"11","key":"9708_CR17","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.oraloncology.2014.08.005","volume":"50","author":"F Petrelli","year":"2014","unstructured":"Petrelli F, Coinu A, Riboldi V, Borgonovo K, Ghilardi M, Cabiddu M, et al. Concomitant platinum-based chemotherapy or cetuximab with radiotherapy for locally advanced head and neck cancer: a systematic review and meta-analysis of published studies. Oral Oncol. 2014;50(11):1041\u20138. https:\/\/doi.org\/10.1016\/j.oraloncology.2014.08.005.","journal-title":"Oral Oncol"},{"issue":"27","key":"9708_CR18","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1200\/JCO.2013.53.5633","volume":"32","author":"KK Ang","year":"2014","unstructured":"Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS, et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol. 2014;32(27):2940\u201350.","journal-title":"J Clin Oncol"},{"issue":"11","key":"9708_CR19","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","volume":"359","author":"JB Vermorken","year":"2008","unstructured":"Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116\u201327.","journal-title":"N Engl J Med"},{"key":"9708_CR20","volume-title":"AJCC Cancer staging manual","year":"2017","unstructured":"Amin MB, Edge SB, Greene FL, et al., editors. AJCC Cancer staging manual. 8th ed. NewYork: Springer; 2017.","edition":"8"},{"key":"9708_CR21","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/hed.21974","volume":"34","author":"AK El-Naggar","year":"2012","unstructured":"El-Naggar AK, Westra WH. p16 expression as a surrogate marker for HPV-related oro-pharyngeal carcinoma: a guide for interpretative relevance and consistency. Head Neck. 2012;34:459\u201346.","journal-title":"Head Neck"},{"key":"9708_CR22","doi-asserted-by":"crossref","unstructured":"Schwartz, L.H.; Liti\u00e8re, S.; De Vries, E.; Ford, R.; Gwyther, S.; Mandrekar, S.; Shankar, L.; Bogaerts, J.; Chen, A.; Dancey, J.; et al. RECIST 1.1\u2014update and clarification: from the RECIST committee. Eur J Dermatol Cancer 2016, 62, 132\u2013137.","DOI":"10.1016\/j.ejca.2016.03.081"},{"key":"9708_CR23","doi-asserted-by":"crossref","unstructured":"KDIGO. Summary of recommendation statements. Kidney Int. 2013;3 (Suppl):5.","DOI":"10.1038\/kisup.2012.77"},{"key":"9708_CR24","volume-title":"Iron deficiency anaemia: assessment, prevention, and control. A guide for programme managers","author":"Anemia: WHO, UNICEF, UNU","year":"2001","unstructured":"Anemia: WHO, UNICEF, UNU. Iron deficiency anaemia: assessment, prevention, and control. A guide for programme managers. Geneva: World Health Organization; 2001. WHO\/NHD\/01.3"},{"issue":"Suppl 1","key":"9708_CR25","doi-asserted-by":"publisher","first-page":"E1554","DOI":"10.1002\/hed.24278","volume":"38","author":"HH Nien","year":"2016","unstructured":"Nien HH, Sturgis EM, Kies MS, El-Naggar AK, Morrison WH, Beadle BM, et al. Comparison of systemic therapies used concurrently with radiation for the treatment of human papillomavirus- associated oropharyngeal cancer. Head Neck. 2016;38(Suppl 1):E1554\u201361.","journal-title":"Head Neck"},{"issue":"5","key":"9708_CR26","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1200\/JCO.2015.63.1671","volume":"34","author":"SM Magrini","year":"2016","unstructured":"Magrini SM, Buglione M, Corvo R, Pirtoli L, Paiar F, Ponticelli P, et al. Cetuximab and radiotherapy versus cisplatin and radiotherapy for locally advanced head and neck Cancer: a randomized phase II trial. J Clin Oncol. 2016;34(5):427\u201335.","journal-title":"J Clin Oncol"},{"key":"9708_CR27","first-page":"904341","volume":"2014","author":"MH Hu","year":"2014","unstructured":"Hu MH, Wang LW, Lu HJ, Chu PY, Tai SK, Lee TL, et al. Cisplatin-based chemotherapy versus cetuximab in concurrent chemoradiotherapy for locally advanced head and neck cancer treatment. Biomed Res Int. 2014;2014:904341.","journal-title":"Biomed Res Int"},{"key":"9708_CR28","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1200\/JCO.20.02072","volume":"39","author":"M Gebre-Medhin","year":"2021","unstructured":"Gebre-Medhin M, Brun E, Engstrom P, et al. ARTSCAN III: a randomized phase III study comparing chemoradiotherapy with cisplatin versus cetuximab in patients with locoregionally advanced head and neck squamous cell cancer. J Clin Oncol. 2021;39:38\u201347.","journal-title":"J Clin Oncol"},{"issue":"9","key":"9708_CR29","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s00066-014-0626-0","volume":"190","author":"A Levy","year":"2014","unstructured":"Levy A, Blanchard P, Bellefqih S, Brahimi N, Guigay J, Janot F, et al. Concurrent use of cisplatin or cetuximab with definitive radiotherapy for locally advanced head and neck squamous cell carcinomas. Strahlenther Onkol. 2014;190(9):823\u201331.","journal-title":"Strahlenther Onkol"},{"issue":"7","key":"9708_CR30","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1200\/JCO.2012.42.3988","volume":"31","author":"JL Lefebvre","year":"2013","unstructured":"Lefebvre JL, Pointreau Y, Rolland F, Alfonsi M, Baudoux A, Sire C, et al. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study. J Clin Oncol. 2013;31(7):853\u20139.","journal-title":"J Clin Oncol"},{"issue":"8","key":"9708_CR31","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1007\/s00066-015-0854-y","volume":"191","author":"N Dornoff","year":"2015","unstructured":"Dornoff N, Weiss C, Rodel F, Wagenblast J, Ghanaati S, Atefeh N, et al. Re-irradiation with cetuximab or cisplatin-based chemotherapy for recurrent squamous cell carcinoma of the head and neck. Strahlenther Onkol. 2015;191(8):656\u201364.","journal-title":"Strahlenther Onkol"},{"key":"9708_CR32","doi-asserted-by":"publisher","first-page":"521","DOI":"10.21873\/anticanres.11344","volume":"37","author":"G Wichmann","year":"2017","unstructured":"Wichmann G, Cedra S, Schlegel D, Kolb M, Wiegand S, Boehm A, et al. Cilengitide and Cetuximab reduce cytokine production and Colony formation of head and neck squamous cell carcinoma cells ex vivo. Anticancer Res. 2017;37:521\u20137.","journal-title":"Anticancer Res"},{"issue":"10166","key":"9708_CR33","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(18)32779-X","volume":"393","author":"ML Gillison","year":"2019","unstructured":"Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein DJ, et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet. 2019;393(10166):40\u201350.","journal-title":"Lancet."},{"issue":"10166","key":"9708_CR34","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0140-6736(18)32752-1","volume":"393","author":"H Mehanna","year":"2019","unstructured":"Mehanna H, Robinson M, Hartley A, Kong A, Foran B, Fulton-Lieuw T, et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De- ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet. 2019;393(10166):51\u201360.","journal-title":"Lancet."}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-09708-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-022-09708-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-09708-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:03:12Z","timestamp":1654646592000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-09708-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,7]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["9708"],"URL":"https:\/\/doi.org\/10.1186\/s12885-022-09708-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,7]]},"assertion":[{"value":"2 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study\u2019s protocol was approved by the Henry Ford Health System Institutional Review Board (IRB number: 13133) and participation informed consent waiver was granted due to the retrospective nature of the research. We confirm that all methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Farzan Siddiqui reports Honoraria for lectures and travel reimbursement from Varian Medical Systems (unrelated to current work); Medical advisory board from Varian Noona. The rest of authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"626"}}